GENOMIC PROFILING OF PANCREATIC CANCER USING EUS-FNA SAMPLES

Abstract

Tumor genomic profiling using next-generation sequencing (NGS) technology enables precision cancer treatment in clinical practice. To date, EUS-FNA plays a pivotal role in the diagnosis of pancreatic lesions. In the era of precision cancer medicine, more effort has been made for tissue acquisition suitable for NGS analysis in EUS-guided sampling. Although the use of EUS-FNA samples for NGS analysis is still controversial in pancreatic cancer, recent studies have reported the feasibility of their use in molecular profiling, including more advanced approaches such as whole-exome/whole-transcriptome sequencing or establishment of patient-derived organoid models. In this review, we discuss the current status and challenges of genomic profiling of pancreatic cancer using EUS-FNA samples.